As acute nonlymphocytic leukemia (ANLL) with inv(l6) (p13q22) or t(16;16)(p13;q22) has been shown to result from the fusion of transcription factor subunit core binding factor (CBFB) to a myosin heavy chain (MYH11). we sought to design methods to detect this rearrangement using reverse transcriptase-polymerase chain reaction (RT-ER). In all of 27 inv(16)(p13q22) and four t(16;16)(p13;q22) cases tested, a chimeric CBFB-MYH11 transcript coding for an in-frame fusion protein was detected. In a more extensive RT-PCR HROMOSOMAL rearrangements associated with hematologic malignancies often become manifest in the fusion of genes. Recently, this has also been shown to be the case in the inv( 16)(p13q22) [inv( 16)] and the related t(16; 16)(p13;q22) [t(16; 16)] associated with acute nonlymphocytic leukemia (ANLL), French-American-British (FAB) type M4 Eo.' These chromosome 16 rearrangements result in the disruption of the myosin heavy chain (MYH11) gene at 1 6~1 3 and the core binding factor (CBFB) gene at 16q22.I.' MYHl1 codes for the heavy chain of smooth muscle myosin, whereas CBFB, named after its murine homolog CBFP, very likely codes for the subunit of a heterodimeric transcription factor (see be lo^).^" In inv(l6) and t(16; 16) patients, translation of the CBFB-MYH11 fusion gene results in chimeric transcripts coding for N-terminal CBFB and C-terminal MYHll sequences.' In two recent reverse transcriptase-polymerase chain reaction (RT-PCR) studies, including a total of 58 inv(l6) and t(16; 16) patients, four different chimeric transcripts coding for in-frame CBFBMYHll fusion proteins were repo1-ted.6'~ The junctions in CBFB are identical and located near the end of the coding region, whereas the junctions in MYHll differ but are all located in the region that codes for the conserved tail of the MYHl1 protein.l,6x7
HROMOSOMAL rearrangements associated with hematologic malignancies often become manifest in the fusion of genes. Recently, this has also been shown to be the case in the inv( 16)(p13q22) [inv ( 16) ] and the related t(16; 16)(p13;q22) [t(16; 16) ] associated with acute nonlymphocytic leukemia (ANLL), French-American-British (FAB) type M4 Eo.' These chromosome 16 rearrangements result in the disruption of the myosin heavy chain (MYH11) gene at 1 6~1 3 and the core binding factor (CBFB) gene at 16q22.I.' MYHl1 codes for the heavy chain of smooth muscle myosin, whereas CBFB, named after its murine homolog CBFP, very likely codes for the subunit of a heterodimeric transcription factor (see be lo^).^" In inv(l6) and t (16; 16) patients, translation of the CBFB-MYH11 fusion gene results in chimeric transcripts coding for N-terminal CBFB and C-terminal MYHll sequences.' In two recent reverse transcriptase-polymerase chain reaction (RT-PCR) studies, including a total of 58 inv(l6) and t(16; 16) patients, four different chimeric transcripts coding for in-frame CBFBMYHll fusion proteins were repo1-ted.6'~ The junctions in CBFB are identical and located near the end of the coding region, whereas the junctions in MYHll differ but are all located in the region that codes for the conserved tail of the MYHl1 protein.l,6x7
Much about the putative function of the human CBFB gene can be derived from its murine homolog, CBFP or PEBP2P, as the genes are 98% homologous at the protein l e~e l . ' .~.~ Murine CBFOPEBP20 codes for at least two isoforms of the &unit of the heterodimeric transcription factor CBF, also known as PEBP2.4.5 CBFPEBP2 is a heterodimer consisting of an a-and a P-unit, binds the enhancers of murine leukemia virus and human polyoma virus, and is believed to play a role in myeloid and T-cell gene expresion.^.'^ Two murine a-units encoded by two different genes have been ide~~tified.'~.'~ One of these murine a-units, encoded by the PEBP2aB gene, is the homolog of the product of the human acute myeloid leukemia (AMLI) gene located at chromosome 21q22.'6,'7 The AMLl gene is disrupted in both the t(3;21)(q26;q22) and t(8;21)(q22;q22) translocations associated with myeloid disorder~.'~-'~ Recently, it has been shown that the human AMLl and murine PEB2aB proteins share an identical, so-called "runt" domain of 128 amino acids (aa) that is responsible for both DNA and protein interactions.'5.",25 The murine CBFPPEBP20 protein does not directly bind to DNA, but it increases the affinity of the heterodimeric CBFPEBP2 protein for DNA by dimerizing with the a -~n i t .~,~ The role of the CBFB-MYH11 fusion protein in leukemogenesis is yet to be understood.
The detection of chimeric transcripts in hematologic malignancies is not only important for diagnostic purposes but also for the identification of the domains in the fused genes that are functionally relevant to leukemogenesis. Here we present the RT-PCR analysis of 27 inv( 16) patients and four t(16; 16) patients and show that, in 30 of the 31 patients studied, an identical in-frame CBFB-MYHll fusion transcript was detected. In the remaining patient, a different inframe CBFB-MYHl 1 fusion transcript was identified. More extensive RT-PCR analysis with different primer pairs, however, allowed us to identify a second CBFB-MYHl1 transcript in 10 of 11 patients tested. The two CBFB-MYHl 1 transcripts, present in the same patient, are caused by alternative splicing. Table 1 ).
MATERIALS AND METHODS

Patient
Detection of CBFB-MYHI I transcripts for diagnostic purposes. Total RNA was isolated from frozen or fresh bone marrow or peripheral blood cells using the acid guanidium thiocyanatelphenollchloroform method." The cDNA was synthesized using 5 pg of total cellular RNA, primer mf at 1.25 pmoVL (Table 2) Table 2 ), and 0.2 g/L bovine serum albumin (BSA) in a total volume of 50 pL. PCR mixtures were incubated at 94°C for 4 minutes before thermal cycling. Thermal cycling was for I minute at 94"C, 1 minute at 60°C and I .5 minutes at 72"C, with cycles repeated 35 times. PCR products were of CBFB-MYH11 transcript (see Fig 1) . 
Primers were synthesized at lsogen Bioscience B.V., Amsterdam, The Netherlands. The underscored sequences in primers ra and rf are in CBFB; the rest of the sequences are i n M Y H l l (see Fig 1) .
* 5"biotinylated. separated on 2.5% agarose gel. As a negative control, all treatments were performed on either bone marrow or peripheral blood cells from non-ANLL-M4 leukemia patients, on healthy individuals, or on K562 cells.
Detectionofdifferentially spliced CBFB-MYHI I trunscripts. Differentially spliced transcripts were detected as described for diagnostic purposes but using the primer pairs cd-mk and ch-mi (Fig I ,  Table 2 ).
Direcr sequencing of PCR products. Biotinylated PCR products were purified on 1% low-melting agarose (Boehringer Mannheim, Mannheim, Germany) and rendered single-stranded using streptavidin-coated magnetic beads as a solid support according to the manufacturer's instructions (Dynal AS, Oslo, Norway)." Nonbiotinylated primers used in RT-PCR were used as sequencing primers (Table  2) . Sequencing reactions were performed using either fluorescein isothiocyanate (FTTC)-labeled deoxyadenosine triphosphate (dATP) and running on the Automated Laser Fluorescent DNA sequencing apparatus according to the manufacturer's instructions (Autoread kit, fluorescent dATP labeling mix, A.L.F.; Pharmacia, Uppsala, Sweden) or "S-dATP according to the manufacturer's protocols (T7 sequencing kit: Pharmacia).
RESULTS
Detection and analysis of chimeric CBFB-MYHIl transcripts. The RNA from 27 inv(l6) patients and four t( 16; 16) patients was subjected to RT-PCR using primer cd in CBFB and primer mi in M Y H l l (Fig 1) . In all cases a product of approximately 415 bp was amplified, with the exception of patient 568193, who showed a 1.3-kb product (Fig 2, lanes 1 and 2) . In some cases, faint bands were seen on agarose gel, possibly indicating the presence of differentially spliced transcripts (Fig  2, lane 1) . The 415-bp PCR fragments derived from patients LB9301, BM82/427, and H91180 were sequenced. Sequence analysis showed that the fragments were identical and derived from a chimeric CBFB-MYH 1 1 transcript that consists of CBFB up to position 495 fused to MYHl1 at position 1921 (transcript type A, Fig l) .'. 3 To demonstrate that the 415-bp PCR fragments identified in the remaining patients were detected due to the presence of transcript type A, primer ra (spanning the transcript type A CBFB-MYH1 1 junction) was used in combination with primer cd in RT-PCR (Fig 1) . In all cases, a 238-bp PCR fragment was amplified, in accordance with the product expected from transcript type A, indicating that this transcript is present in all of these patients (Fig 2, lane 3 ; Table 1 ). Sequence analysis of the 1.3-kb PCR fragment derived from patient 568193 showed that the transcript in this patient con- cd-mi, we pcr-I'ormcd IIT-PCR on the RNA from nine inv( 16) and ~w o t( i 6; 16) patients using the primer pairs cd-Ink and ch-mi (Fig I; Table I ) . Using primer pair cd-Ink, a 460-bp I T R fragment was detected in only one case (patient KM82/427, Fig 2, lane 4) . Sequence analysis of the 460-bp PCR fragrncnt showed a chimeric CBFR-MYH 1 I transcript that consists of CBFH up t o position 526, fuscd to MYH I 1 at position 1715 (transcript type E , Fig l) .'.' The fusion occurs in such a way that the reading frame of the fusion protein is maintained (scc Discussion). using primer pair ch-mi, a 430-bp PCR fragment (consistent with the transcript type E) was idcntilieti i n patient BM821427 (not shown). However, in C) of the I O remaining patients, a 225-ly PCR fragment was unpliticd alier RT-PCK (Fig 2, lane S) . The 225-bp PCR fragment from patient B92/16C) was sequenced. Sequence analysis showed a chimeric CBFB-MYH I 1 Lrnnscript, consisting of CBFH fused at position S26 to MYHl 1 at position 1921 (transcript type F, Fig l) .',' The junction in CBFB a t position S26 in transcript type F is not in-frame, resulting in an out-ol-lramc M Y H I I and, hence, ;I truncated CBFR subunit. To verify that the 225-hp PCR fragments identitied in the remaining patients were detected due t o the presence of transcript type F, primer rf (spanning the transcript type F junction) was used in combination with primer cd i n RT-PCK (Fig l) . I n a l l cases, a 269-bp PCII fragment was amplitied in accordance with the product expected from transcript type F, indicating that this tnlnscript is present in a l l these patients (Fig 2, lane 6 ; Table I ). In the remaining patient H85/762 (case g), no PCR product was detected on agarose gel after RT-PClI using cither primer pair cd-mk o r ch-mi.
DISCUSSION
In all inv(l6) and t( 1 6 ; 16) cases, a chimeric CBFRMYHl l transcript was dctccted with the discussed RT-PCK conditions and primer pair cd-mi. I n one case, transcript type D was detected, whereas in the remaining 30 cases, transcript type A was detected (Fig 1 ; Table 1 ). In two recently reported RT-PCR studies including a total of 58 inv(l6) and t( 16; 16) patients, four different chimeric CBFB-MYHI 1 transcript types were identified (types A through D , Fig l) .".7 The clear predominance of transcript type A in these studies confirms our results. Because we could readily detect the fargest CBFB-MYHI 1 transcript, type D, reported in a total of 89 inv( 16) and t(16; 16) cases (including our 31), we believe that with the methods we describe in this study, a reliable diagnosis can be made by detecting chimeric CBFB-MYHI 1 transcripts as a routine laboratory test for the ANLL M4 Eospecific rearrangement. Furthermore, the detection of chimeric CBFB-MYH 1 1 transcripts in inv( 16)/t( 16; 16) patients after treatment could also compose a sensitive test to monitor the remi~sion.'.~ Using primer pairs cd-mk and ch-mi in RT-PCR, we detected two new chimeric CBFB-MYHI l transcripts in I O of 1 1 cases tested. In one case, transcript type E was detected, while in nine cases, transcript type F was identified (Fig I ;  Table l) . In one case, no differentially spliced transcript was detectable on agarose gel after RT-PCR using either primer VAN DER REIJDEN ET AL pair cd-mk or ch-mi (case 8). Further hybridization experiments should determine the presence or absence of differentially spliced transcripts in this case.
The faint bands seen on agarose gel after RT-PCR using primer pair cd-mi (Fig 2, lane 1) might represent as yet unidentified differentially spliced transcripts, as these bands are not derived from the type E or F transcripts. This can be concluded due to the fact that the transcript types E and F are larger than transcript type A detected in this experiment, whereas all the faint bands are smaller.
It appears that transcript type F is less abundant than transcript type A in the leukemic samples. This may be concluded from the absence of a type F band after amplification with primer pair cd-mi. This primer pair, which efficiently amplifies the type A cDNA, would be expected to amplify type F equally efficiently, given that it is only 31 bp longer. The fact that primer pair ch-mi (incapable of detecting the type A transcript) is required for the detection of the type F transcript suggests that the latter form is much less numerous.
The main difference between transcript types A through D and E/F is that the latter are 31 nucleotides (nt) extended on the 3' CBFB end (Fig l) . To investigate whether alternative splicing could be responsible for the presence of different chimeric CBFB-MYH 1 1 transcripts in the same patient, we sequenced parts of the CBFB gene. The 3 I-nt CBFB extension present in transcripts E and F was found to originate from the 3' end of CBFB exon 5 (P. Liu, personal communication, November 1994) .' In the CBFB cDNA clone (RL9A) isolated from a human fetal brain cDNA library, the 31 nt from position 495 to 526 are present.' However, we have isolated a CBFB cDNA clone (LISQ8) from a human striatum cDNA library lacking these 31 nt (not shown). Considering that the last 31 nt of exon 5 in CBFB cDNA clones can be either present or absent, it can be concluded that CBFB transcripts are alternatively spliced, in which two splice donor sites share the same splice acceptor site. Apparently, a cryptic splice donor site occurs in CBFB, 31 nt inwards from the end of exon 5, which can be used in striatum. Because this alternative splicing in CBFB results in frame shifts and is located at the 3' end of the coding region, the wild type (wt) CBFB isoforms must differ at their C-terminal region (Fig 3) . The functional significance of this polymorphism remains unknown and requires further study. Murine CBFPPEBWP transcripts are spliced exactly the same way as human CBFB transcripts (Fig 3) ?' The 3 1 nt at the end of CBFB exon 5 that can be omitted in splicing are 100% homologous between mice and humans, suggesting that the C-terminus plays an important role in CBFB function. As the murine CBFfiPEBP2P isoforms are able to dimerize with PEBP2a units, it is likely that the different C-termini in the CBFPPEBP20 proteins in combination with different PEBP2a proteins render differential regulatory functions to the heterodimeric murine CBFPEBP2 protein.
However, it is clear that alternative splicing in the primary CBFB-MYHI 1 transcripts in the leukemic inv(16)/t(16; 16) cells is responsible for the presence of at least two different chimeric CBFB-MYH11 transcripts in the same patient. Transcript type E in patient BM82/427 is particularly remarkable in that both the CBFB and MYHI1 segments differ when compared with the other transcript identified in this patient, type A. In transcript type E, the CBFB fragment is 31 nt extended on the 3' end, and the MYHl1 fragment is 206 nt extended on the 5' end (Fig 1) . Thus, a total additional 237 nt are present, and the reading frame, which would have been disrupted by the extra 31-nt CBFB, has been restored by the inclusion of the extra 206-nt MYHll. Considering that alternative splicing is frequently seen in myosin genes, it is very likely that the alternative splicing in primary CBFBMYHl1 transcripts is brought about by alternative splicing signals in the MYHl1 segment?'
The strong correlation between &L M4 Eo and inv( 16) and the consistent detection of an in-frame fusion between CBFB and MYHll in all patients suggest that both fusion partners CBFB and MYHl1 are essential for leukemogenein transcript type F (detected in 9 of 11 patients tested) results in a stop codon located at the third codon after the CBFB-MYHI 1 junction and, hence, a slightly truncated CBFB, termed CBFBF (Fig 3) . The normal CBFB mRNA contains in its 3' untranslated region (UTR) numerous clusters of A and U nt, including many copies of AUUU(U)A, frequently found in transcripts with a high turnover rate.29 The fusion mRNAs have lost these sequences and may, therefore, be more stable, leading to a higher protein expression. If the absence of 3' UTR destabilizing motifs contributes to a higher protein expression, then this should be seen by monitoring the relative quantification of the fusion and wt CBFB transcripts and proteins. It remains to be seen whether CBFBF, as well as the in-frame CBFB-MYH1 I fusion proteins, play a role in leukemogenesis, sis.l,6,7 Interestingly enough, the out-of-frame CBFB junction 
